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AbstrAct
Introduction Melanoma is the fifth most common 
cancer in the UK. Incidence rates have quadrupled over 
the last 30 years and continue to rise, especially among 
younger people. As routine screening of the general 
population is not currently recommended in the UK, a 
focus on secondary prevention through early detection 
and prompt treatment in individuals at increased risk 
of melanoma could make an important contribution to 
improve melanoma outcomes. This paper describes 
the protocol for a phase II, multisite, randomised 
controlled trial, in the primary care setting, for patients 
at increased risk of melanoma. A skin self-monitoring 
(SSM) smartphone ‘App’ was used to improve symptom 
appraisal and encourage help seeking in primary care, 
thereby promoting early presentation with skin changes 
suspicious of melanoma.
Methods and analysis We aim to recruit 200 participants 
from general practice waiting rooms in the East of 
England. Eligible patients are those identified at higher 
melanoma risk (using a real-time risk assessment tool), 
without a personal history of melanoma, aged 18 to 75 
years. Participants will be invited to a primary care nurse 
consultation, and randomised to the intervention group 
(standard written advice on skin cancer detection and sun 
protection, loading of an SSM ‘App’ onto the participant’s 
smartphone and instructions on use including self-
monitoring reminders) or control group (standard written 
advice alone). The primary outcomes are consultation 
rates for changes to a pigmented skin lesion, and the 
patient interval (time from first noticing a skin change 
to consultation). Secondary outcomes include patient 
sun protection behaviours, psychosocial outcomes, and 
measures of trial feasibility and acceptability.
Ethics and dissemination NHS ethical approval has been 
obtained from Cambridgeshire and Hertfordshire research 
ethics committee (REC reference 16/EE/0248). The 
findings from the MelaTools SSM Trial will be disseminated 
widely through peer-reviewed publications and scientific 
conferences.
trial registration number ISCTRN16061621.
IntroductIon
Malignant melanoma is the leading cause 
of skin cancer deaths in the UK with 2459 
in 2014.1 Melanoma skin cancer incidence 
has quadrupled over the last 30 years, and 
continues to rise.2 Although melanoma is 
more common with increasing age, around 
half of melanoma in the UK each year are 
diagnosed in people aged <65.3 4 Risk factors 
include fair skin, family history of melanoma, 
multiple naevi and sun damage. Melanoma is 
associated with significant morbidity, and the 
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strengths and limitations of this study
 ► The MelaTools Skin Self-Monitoring (SSM) Trial is 
among the first, in the UK or internationally, to risk 
stratify the primary care population in order to target 
an intervention to improve timeliness of melanoma 
detection.
 ► It uses digital technology to encourage people at 
higher risk of melanoma to self-monitor their skin 
and present to their physician with any concerns.
 ► The trial aims to establish the feasibility and 
acceptability of undertaking SSM among people 
at higher risk of melanoma; it will also report 
on consultation rates and includes 6-month and 
12-month participant follow-up.
 ► As this is a feasibility trial, the main limitation is 
that the small sample size will limit meaningful 
interpretation of the clinical outcomes; furthermore, 
the sample may not be fully representative of the 
UK adult population as it excludes people who do 
not own a smartphone, and those with physical 
disorders severe enough to hamper smartphone 
use.
 ► Information from this trial will enable planning of a 
larger phase III trial to further assess the impact of 
the use of a smartphone App to encourage SSM on 
clinical outcomes for melanoma.
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thickness of the lesion at diagnosis is the most important 
prognostic factor: stage 1 disease has 5-year survival rates 
of over 95%, compared with <25% for stage 4 disease.5 
The UK has lower 1-year and 5-year melanoma survival 
rates than comparable countries in Europe.6 Diagnostic 
delays are thought to contribute to this, and there is 
evidence of avoidable delay.7 Evidence from the SCREEN 
project in Germany, conducted between 2003 and 2004, 
suggested that population screening may have an impact 
on melanoma incidence and 5-year mortality.8 9 However, 
this evidence is controversial, and routine screening of 
the general population is not currently recommended 
anywhere worldwide, although some countries (Australia, 
New Zealand, Germany, the Netherlands and the UK) 
recommend regular skin checks and/or self-examina-
tion for certain subsets of patients at increased risk of 
melanoma.10 Therefore, a focus on targeted population 
screening could make an important contribution to 
melanoma outcomes through early, timely detection and 
prompt treatment.
Patient pathways to presentation and management in 
primary care are key determinants in cancer outcomes. 
When compared with people diagnosed with other 
cancers, those diagnosed with melanoma have the second 
longest median time between first noticing a symptom 
and presenting to primary care (patient interval).11 12 The 
patient interval could potentially be reduced by providing 
patients with clear information on the signs and symp-
toms of melanoma and guidance on monitoring skin 
changes,13 through community campaigns such as the Be 
Clear on Cancer skin cancer campaign.14 More targeted 
approaches could focus on individuals at higher risk.
Smartphones offer considerable potential to promote 
earlier presentation by people with cancer, including 
melanoma.15 More than 70% of the UK adult popula-
tion now own a smartphone (Techtracker), and there 
are many smartphone applications (‘Apps’) focusing on 
health issues, presenting new opportunities for risk assess-
ment, symptom appraisal, monitoring symptoms and signs 
over time, and cues to seek professional advice. Further-
more, up to 75% of melanomas are detected by people 
or their family/friends, rather than healthcare profes-
sionals. To maximise the effectiveness of skin self-mon-
itoring (SSM), the person performing the examination 
should be able to identify skin changes and features of 
skin lesions which could indicate melanoma, yet recent 
studies have demonstrated that suspicious signs of skin 
cancer may not be widely known.13 16 Important interna-
tional evidence has shown that it is possible to educate 
patients and the public: newly diagnosed Italian mela-
noma patients who performed self-skin examination were 
found to have thinner tumours,17 and Australian patients 
with melanoma were found to adhere to medical advice 
on skin self-examination during follow-up care.18 A recent 
Scottish study has demonstrated that patients with mela-
noma are prepared to use digital technology to support 
them in conducting SSM during follow-up.19 We there-
fore set out to explore using mobile technology for SSM 
among people at higher risk of melanoma in the primary 
care setting to encourage timely consultation for possible 
melanoma.
Preliminary phase I research
Guided by the Medical Research Council framework on 
developing and evaluating complex interventions,20 three 
phase I studies were conducted to (1) assess the feasibility 
and acceptability of defining a population at higher risk 
of melanoma from UK general practice; (2) review the 
availability of suitable smartphone SSM Apps and (3) 
pilot the intervention.
Assessing the feasibility and acceptability of defining a population 
at higher risk of melanoma from UK general practice
The MelaTools-Q Study findings have already been 
reported.21 Briefly, 7742 patients (86% of those 
approached) were recruited from the waiting rooms of 22 
general practices in three UK regions: Eastern England, 
Northeast Scotland and North Wales. Using tablet 
computers, they completed an electronic questionnaire 
incorporating the Williams melanoma risk prediction 
model,22 including items relating to seven risk factors: 
gender, age, natural hair colour at age 15, number of 
severe sunburns aged 2–18, prior non-melanoma skin 
cancer, number of raised moles on both arms and density 
of freckles on both arms before age 20. The study showed 
that, after weighting to the age and sex distribution, the 
lower and upper quartile cut-offs used by Williams et al, 
25 and 34, would allow between 4% and 20% of the popu-
lation to be identified as higher risk, and those groups 
would contain 30% and 60%, respectively of individuals 
who would develop melanoma. Therefore, real-time risk 
assessment for melanoma in UK primary care is both 
feasible and acceptable.
Reviewing the availability of suitable smartphone SSM Apps
Our initial review, conducted in July 2014, identified 39 
smartphone Apps available from Apple and Android App 
online stores.23 However, when the same search strategy 
was re-run in September 2015, eight new SSM Apps were 
identified, while eight of the previously identified SSM 
Apps were no longer available. Among the 39 newly iden-
tified SSM Apps, 11 were not available in both Apple and 
Android App stores; 10 did not include a monitoring 
function; 5 did not include photography of skin lesions; 
5 had poor functionality; 2 were not available in England; 
2 were classified as medical devices; 1 was under develop-
ment, 1 one had no reminder feature, deemed vital for 
monitoring functionality. Two SSM Apps were considered 
potentially most suitable to include in the intervention 
(see figure 1).
Piloting the intervention
Qualitative research, using focus groups and interviews, 
was conducted with individuals at increased risk of mela-
noma to provide in-depth understanding of consumer 
views on the usefulness and usability of the two selected 
SSM Apps. Eight people at increased risk of melanoma 
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Figure 1 The availability and suitability of smartphone skin self-monitoring (SSM) Apps for the MelaTools SSM Trial.
were recruited for two focus groups from a local mela-
noma patient support group; three of their relatives also 
took part. People were also recruited in the waiting rooms 
of two suburban general practices and completed the 
Melatools-Q risk assessment tool.21 Five identified to be at 
increased risk of melanoma were invited to participate in 
two other focus groups. A total of 16 participants tested at 
least one of the SSM Apps. The participant characteristics 
are shown in table 1.
The four focus groups were conducted by an experi-
enced qualitative researcher (KM) and research assis-
tant (RL), either at the recruiting general practice or 
university premises; each lasted approximately 90 min, 
was audiorecorded and the recordings transcribed 
verbatim. Each participant was initially helped to load the 
two SSM Apps on their smartphones, and given time to 
familiarise themselves with their use. Thematic analysis24 
showed that, overall, participants in all four groups and 
at all strata of increased risk of melanoma felt that using 
a SSM App would be helpful and achievable. Many felt 
that using a SSM App would enhance their current SSM 
habits: ‘I look at the moles and I just keep an eye on them’ 
(Male, above-population risk, group 3). Many also felt that 
using a SSM App could help reduce their worry about 
developing skin cancer: ‘cos my dad had cancer recently 
so [my mother] says we’re at a higher risk, so she goes 
on about that’ (Female, above-population risk, group 4). Some 
felt that using a SSM App would guide their help-seeking 
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Table 1 Piloting the intervention–consumer characteristics
Participants 
(n=16)
Risk of melanoma
  High risk of melanoma (treated melanoma) 8
  At above population risk 5
  Unknown risk (relative of high risk 
participant)
3
Gender
  Male 8
  Female 8
Age
  <35 years 2
  36–44 years 1
  45–54 years 3
  55–64 years 7
  65–74 years 3
Ethnicity
  White British 15
  White other 1
Education (highest qualification)
  GCSE or equivalent* 1
  A level or equivalent† 3
  Vocational 2
  Undergraduate degree 3
  Postgraduate degree or professional 
qualification
7
Employment status
  Student 1
  Work part time 5
  Work full time 4
  Homemaker 1
  Retired 5
Index of Multiple Deprivation quintiles
  Least deprived 1 8
   2 5
   3 2
   4 0
  Most deprived 5 0
  Unknown 1
*GCSE, an academic qualification awarded in a specified subject, 
generally taken in a number of subjects by pupils aged 14–16 in 
England and Wales.
†A level, same, generally taken aged 16–18.
GCSE, General Certificate of Secondary Education.
behaviour for skin changes or moles: ‘It’s that knowledge, 
if it’s, you know, three months, whatever it is, if you can 
actually say look there is a visible change then you're 
getting a bit of information that they probably could do 
with…you’ve got physical evidence, and then the confi-
dence to go to…’ (Male, above-population risk, group 
4). Several also commented on additional features on 
smartphones which might help prevent development of 
future melanomas: ‘I’ve got a UV index on my phone so 
I can always check what that is, so putting sun cream on.’ 
(Male, high risk, group 2).
The five participants recruited via primary care were 
invited to complete a diary 1 and 2 months later, and then 
participate in a telephone interview after the third month. 
Diary records and thematic analysis of the interviews (as 
above) confirmed that participants used many features of 
both SSM Apps, including taking photographs, mapping 
these to body parts, comparing photographs over time and 
using the analysis function (available in only one of the 
Apps). There was unanimous agreement between partici-
pants about the App which was easier to use (MySkinPal), 
and most reported that they would continue to use it 
after the study, particularly as they found the App’s noti-
fications the most efficient method to prompt them to 
complete future SSM. Despite this, several also reported 
that they found taking photographs quite challenging, 
and that they had to recruit a family member to assist 
them in taking photographs to compare skin changes 
over time. Furthermore, while regularly self-monitoring 
their skin during the study, most participants reported 
worrying about skin cancer ‘sometimes’, seeking further 
information about skin changes or moles via the internet, 
speaking to friends and family, and visiting their general 
practice.
In conclusion, this preliminary phase I work enabled 
consumer choice of the more user-friendly SSM App, 
resulted in modifications to the language used in the trial 
consultation and led to the development of the Mela-
Tools SSM Trial.
The trial aims to assess the effect of using an SSM App 
compared with standard information about detecting 
skin cancer on consultation rates and the patient 
interval (the time from first noticing a skin change/
mole to consultation with a primary care healthcare 
professional) among patients at increased risk of 
melanoma, identified via primary care. In addition, to 
obtain preliminary estimates of effect across a range of 
outcome measures to inform selection of the primary 
outcome for a definitive phase III trial. We hypothesise 
that primary care patients at higher risk of melanoma 
will seek help more rapidly after noticing skin changes 
when using an SSM App compared with using standard 
written information.
MEthods And AnAlysIs
study design and setting
The phase II trial is a multisite randomised controlled 
trial (figure 2), set in 11 general practices across Eastern 
England. Those who meet the eligibility criteria and 
consent to participate are randomised 1:1 into either the 
control or intervention group. Randomisation is being 
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Figure 2 MelaTools Skin Self-monitoring (SSM) Trial flowchart. 
performed using an online system provided by the Clin-
ical Trials Unit based at Kings College London.
study participants
Eligibility criteria
Eligible participants are individuals aged between 18 and 
75 years who own a smartphone (Apple or Android), 
and, on completion of the Melatools-Q risk assessment 
tool,21 are found to be at increased risk of melanoma. 
Participants are able to read and write English and to give 
informed consent.
Exclusion criteria
Exclusion criteria are previous diagnosis of melanoma, 
severe psychiatric or cognitive disorders, or a physical 
disorder severe enough to inhibit the use of a smartphone.
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Participant recruitment
Potentially eligible individuals are approached by 
research nurses or research assistants in GP waiting 
areas at different times of the day and different days of 
the week, in order to ensure that a broad range of ages, 
gender and educational level are approached. Those 
meeting initial screening criteria are given a tablet 
computer that includes a short version of the participant 
information sheet and an online consent form agreeing 
to have their risk assessed and be considered for the trial. 
They complete the MelaTools Q study risk assessment 
tool21 which stratifies respondents into ‘population risk’ 
(majority) and ‘increased risk’, using a cut-off score in 
the Williams model of 25. People at ‘population risk’ are 
thanked and given the Cancer Research UK leaflets on 
risk factors of melanoma and melanoma detection advice. 
People at increased risk are invited to participate in the 
trial, and given the full-length trial Participant Informa-
tion Sheet and an appointment time within 14 days for 
the primary care nurse trial consultation. Individuals not 
wishing to take part are asked their reason for declining.
Control and intervention groups and randomisation
Informed written consent is obtained from all participants 
at the start of the trial consultation (online supplemen-
tary file S1). After completion of a baseline question-
naire, the trial nurse guides the participant through the 
Cancer Research UK leaflets on ‘Be SunSmart cut your 
cancer risk’ and ‘Skin cancer—How to spot the signs and 
symptoms’. Online randomisation is then performed: 
those randomised to the control group are thanked for 
their participation and both groups are given the Cancer 
Research UK leaflets to take home.
Intervention group
Participants randomised to the intervention group are 
assisted with loading the SSM App onto their smartphone 
by the trial nurse, who continues by giving instructions 
on its use, supported by written instruction sheets. The 
core functions of the App, MySkinPal, include full body 
scan, body diagrams, photo source and browser, informa-
tion on the signs of melanoma, regular reminders, ability 
to select moles to share with a doctor and motivation to 
use including awards/achievements. The nurse ensures 
that the App’s monthly reminder notification is switched 
on to prompt each participant regularly. Finally, each 
intervention participant is given an Apple Apps store/
Google Play voucher (up to £5) to pay for the App.
outcomes and measures
The primary outcomes of this trial are consultation rates 
for pigmented skin lesions and the patient interval. Consul-
tation rates for changes to an existing pigmented skin 
lesion or concerns about a new pigmented skin lesion 
for 12 months before the trial and 12 months after the 
trial consultation will be collected via searching general 
practice electronic medical records using a clinical notes 
audit for every participant. The patient interval is the 
time from first noticing a skin change to first consulta-
tion. These data will be collected monthly by searches of 
general practice electronic medical records for all skin 
changes or pigmented skin lesions presented to their 
general practitioner (GP) or practice nurse during the 12 
months following the trial consultation. When a partici-
pant consults about a pigmented skin lesion, they receive 
a skin questionnaire to complete. This skin questionnaire 
uses the symptom study instrument modified for mela-
noma symptoms. The instrument is a participant-com-
pleted questionnaire collecting data on symptoms and 
their duration prior to consultation, validated in prospec-
tive studies examining symptom and patient factors 
associated with longer time to diagnosis for colorectal, 
lung and pancreatic cancer.25–27 The skin questionnaire 
comprises 10 items starting with a free text response to 
‘What was the first skin change or mole you noticed that 
made you think something might be wrong?’ Each item 
includes the subitems: ‘When did you first notice this?’ 
and ‘When did you first tell your GP or nurse?’
Secondary measures and outcomes (measured at base-
line, 6 and 12 months) include:
1. demographics and clinical variables: age, gender, marital 
status, postcode, highest education level, occupation, 
history of skin cancer (melanoma, squamous cell 
carcinoma, basal cell carcinoma), skin and hair type 
(density of freckles on arms before age 20, natural 
hair colour at age 15, number of severe sunburns 
aged 2–18), number of raised moles on both arms, 
measured at baseline only,21 22 collected as part of the 
baseline eligibility assessment;
2. sun protection habits scale developed by Glanz et al in the 
USA for a multicomponent skin cancer prevention 
programme; this comprises five items measured using 
a four-point Likert scale, and relating to use of sun 
protection, sun and sunbed habits, and episodes of 
sunburn in the previous year,28 as we hypothesise that 
the App reminders will prompt people and reinforce 
the messages on sun protection;
3. skin self-examination benefits and barriers scale: validat-
ed by Manne and Lessin in the USA among melano-
ma survivors, and developed from previous work on 
mammography and family members of patients with 
colorectal cancer.29 The benefits scale has seven items 
(α=0.71) and the barriers scale has 10 items (α=0.74);
4. Melanoma Worry Scale (MWS) validated by Moye et al in 
the USA,30 and adapted from the Breast Cancer Worry 
Scale;31 this measure comprises four items, scored 1 to 
4, with possible scores ranging from 4 to 17, and high-
er scores indicating higher levels of worry
5. Perceived melanoma risk: drawn from Manne and Les-
sin’s measures,29 these two items have been widely 
used for melanoma and other cancer risk assessments 
to assess estimated percent risk of developing melano-
ma, and perceived risk compared with a person of the 
same age (relative risk);
6. Self-efficacy for consulting without delay: A 10-item 
self-completed scale summed to score 10–100, was 
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used in a primary care trial for lung symptoms 
and showed good internal reliability (Cronbach 
α=0.85).32 33 It has been adapted for this trial, and 
reduced to eight items, for example. ‘How confident 
are you that you can make an appointment to see a 
doctor when…… you can’t get an appointment with 
your usual doctor?’;
7. Hospital Anxiety and Depression Scale: This 14-item 
self-completed scale has been widely used to mea-
sure distress and has been extensively validated and 
shown to perform well in a wide range of popula-
tions (mean Cronbach α=0.82; sensitivity and spec-
ificity 0.80)34 ;
8. 12-Item Short Form Survey (SF-12) quality-of-life scale: a 
12-item version of the SF-36 that is widely used and 
validated to measure functional health and well-
being,35 for example, ‘During the past 4 weeks, have 
you had any of the following problems with your work 
or other regular daily activities as a result of your 
physical health?… … ’
Other outcome measures include:
9. trial feasibility and acceptability, including data on patient 
recruitment and attrition rates, reasons for attrition, 
response rates to skin symptom questionnaires for 
measuring the patient interval to inform decisions 
about a future phase III trial;
10. melanoma incidence across participating practices to 
contextualise trial findings and after 5 years. This will 
be identified through GP electronic medical records 
and the National Cancer Registration Service.
Measurement timings and study end points
At the trial consultation, all participants will be fully 
informed about trial follow-up procedures. The partic-
ipant-reported measures (numbers 1–8 above) are 
completed in person at baseline, and online at follow-up 
1 (6 months) and follow-up 2 (12 months), with the 
exception of the skin symptom questionnaire as already 
described, which is sent to participants by postal mail 
within a month of any consultation for skin changes or 
pigmented skin lesions.
After trial completion, a final audit of the GP elec-
tronic medical records will be run to identify all skin 
consultations for the 12 months during the trial as well 
as the previous 12 months. Melanoma incidence find-
ings will also be collected at the end of the 12-month 
follow-up period and at 5 years. These data will not be 
collected for participants who formally withdraw from 
the trial.
Participant data and study management
All participants are allocated a unique identifying code. 
Melanoma risk assessment data, baseline question-
naire and follow-up questionnaires data are stored on a 
custom built database on a secure server hosted by the 
Outcome Registry Intervention and Operation Network, 
Clinical Neurosciences Department at the University of 
Cambridge.
sample size consideration
Based on our recent MelaTools Q study with an identical 
screening step (response rate of 86%), we anticipate that 
we will need to approach approximately 2000 people 
from 10 general practice waiting rooms for about 1600 to 
complete the Melatools Q risk assessment tool.23 About 
25%, 400 people, will be identified as increased risk and 
be eligible to participate in the trial. Based on previous 
research, we would expect approximately 50% of these 
to attend their trial consultation and undergo randomisa-
tion in order to reach our target of 200 participants.
We will use information on recruitment, attrition and 
data completeness, and preliminary estimates of effect 
sizes where appropriate, to inform the sample size calcu-
lation for a future phase III trial.
statistical analysis
All randomised patients will be considered eligible for 
inclusion in the analysis in accordance with the intention-
to-treat analysis principle. As this is a phase II trial, fully 
describing and characterising the extent and nature of 
the missing data is an important part of the analysis. For 
the outcome analysis, appropriate methods for dealing 
with missing endpoint data will be informed by a blinded 
review of the data; however, assuming that this is appro-
priate, we plan a series of extreme case-sensitivity analyses, 
where missing data will be replaced with the 2.5th and 
97.5th centiles of the non-missing measured outcomes to 
assess the maximum potential impact on the results of the 
trial. The baseline characteristics of the two arms will be 
described using summary statistics. Possible consent bias 
will be assessed by comparing demographic and clinical 
variables of participants with those who declined partici-
pation, and possible differential attrition will be assessed 
by comparing baseline characteristics of those who with-
draw or die with those who remain in the trial. In addi-
tion, we will analyse the missing data to understand the 
potential impact on the required sample size, and to assess 
whether and where possible bias may arise, and there-
fore be minimised, in the future design for the efficacy 
phase III trial. We will describe the amount (percentage) 
of missing data in all outcome measures at baseline and 
follow-up, and evaluate the relationship between missing 
data and treatment assignment using unadjusted Χ2 tests. 
We will describe whether missing data occur differentially 
between outcomes. These comparisons will be performed 
using a two sample t test (or non-parametric equivalent) 
for continuous variables and Χ2  test for categorical 
variables.
The primary analysis will be a comparison between the 
two groups on the consultation rate for skin changes/
pigmented skin lesion using a Poisson regression model. 
Comparisons between groups on binary secondary 
endpoints will be performed using logistic regression. 
Comparisons between groups on continuous secondary 
endpoints will be undertaken using a linear model that 
includes the baseline value where applicable. A linear 
model may not be appropriate for the secondary outcome 
group.bmj.com on December 1, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
8 Mills K, et al. BMJ Open 2017;7:e017934. doi:10.1136/bmjopen-2017-017934
Open Access 
patient interval, as this is expected to be right skewed.36 
We will explore the nature and extent of the skewness and 
analyse patient interval using a linear model if possible, 
adopting other approaches as appropriate, including 
transformation or categorisation of the patient interval, 
or methods for statistical inference based on bootstrap 
resampling. The analyses performed on the primary and 
secondary endpoints will be repeated adjusting for addi-
tional baseline covariates as part of a sensitivity analysis. 
Point estimates of the intervention effect will be presented 
with 95% CIs and two-sided P values. Unadjusted P values 
from secondary analyses will be interpreted in proper 
context and be clearly labelled.
Ethics and dissemination
Ethical approval
This trial is sponsored by the School of Clinical Medicine 
at the University of Cambridge. Ethical approval for the 
MelaTools SSM trial was granted on 11 July 2016 by the 
Cambridgeshire and Hertfordshire NRES research ethics 
committee (reference number 16/EE/0248). Health 
Research Authority approval (HRA) was granted on 22 
July 2016. R&D approvals have been obtained from the 
relevant Trusts. All substantial amendments are approved 
by the NHS Research Ethics committee responsible for 
the trial, in addition to approval by HRA and NHS R&D. 
Investigators are kept up to date with relevant changes via 
regular management group meetings.
Data monitoring
Due to the non-medicinal and low-risk nature of the 
trial, a data monitoring committee will not be needed. 
The trial steering committee (the CI, collaborators 
and researchers, statistician and PPIE representa-
tives) will meet six monthly from the start of the trial 
and will monitor trial progress, approve a data anal-
ysis plan, and will ensure the trial runs in accordance 
with the protocol and applicable standard operating 
procedures. The CI will take responsibility for data 
monitoring and ethics, and will be responsible for 
communicating important protocol modifications to 
relevant parties.
Expected findings, implications and dissemination
Twelve-month follow-up will complete in January 2018. We 
expect that the trial will prove to be both feasible and accept-
able to participants without causing them significant anxiety 
or harm. We do not expect to be able to draw any signifi-
cant clinical conclusions from this small trial; therefore, we 
expect to be use these findings to support a funding appli-
cation for a larger phase III trial aiming to be sufficiently 
powered to enable evaluation of clinical outcomes. We are 
also interested in further work exploring the usefulness of 
different apps for different groups of consumers.
We will submit the findings of our research for publication 
in highly cited and open access peer-reviewed journals, and 
the findings will also be presented at national and interna-
tional conferences. We will also provide a summary of our 
findings on the MelaTools programme website  MelaTools. 
org.
trial progress
The study was registered in the ISRCTN Trials Registry on 17 
August 2016, the first participant was recruited on 22 August 
2016, enrolment was completed on 6 January 2017 and the 
participants continue to be followed up in the study, with an 
estimated finish date of end January 2018.
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